The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•18 April 2026•

1 min read

Cosmos Health to Launch Cur18 Supplement in US Market During Q2

Key Facts

1Cosmos Health plans to launch Cur18, a patented joint health supplement, in the US market during Q2.

2The new product features 39x higher bioavailability compared to standard curcumin extracts.

Cosmos Health (COMS) has announced its strategic expansion into the US market with the upcoming launch of Cur18, a patented joint health supplement, scheduled for the second quarter. This next-generation curcumin therapy utilizes advanced technology to significantly enhance absorption rates and therapeutic efficacy. According to company reports, Cur18 features a bioavailability that is 39 times higher than standard curcumin extracts currently available. The move represents a significant step in the company's growth strategy within the US nutraceuticals sector. By introducing clinically studied products, Cosmos Health aims to capture a larger share of the wellness market and diversify its revenue streams. Market analysts view this launch as a positive development for the company's product portfolio, though its impact on the micro-cap stock remains subject to broader market conditions.